Goldman Sachs (GS)
NYSEFinancialsCapital MarketsSnapshot 2026-07-08
$1028.96-1.34%
Close 2026-07-08 · 1-day change
Reading GS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GS free→NYSEFinancialsCapital MarketsSnapshot 2026-07-08
Reading GS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GS free→QuarterlyIQ Insights · GS
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 10 valuation methods, at three horizons. Current price $1028.96. As of 2026-07-09. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $1,029 GS trades at 19× p/e, below its 24× p/e peer median, but our blended $1,030 fair value is roughly in line with the price. We hold it with medium confidence: quality doesn't explain valuation multiples in this sub-industry, so the peer comparison is a weak guide. Analysts target $900–$1,150. Not investment advice.
$900.00 – $1150.00 (median $1070.50) · 8 analysts · as of 2026-07-07
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $1070.50 | — | — | Analyst | high |
| ddm gordon | 12M | $223.80 | — | — | TTM | high |
| graham number | 12M | $700.58 | — | — | TTM | high |
| Peer P/B | 12M | $1028.96 | 2.6 | 398.64 | TTM | high |
| Peer P/E | 12M | $1293.49 | 23.6 | 54.72 | TTM | high |
| Peer P/S | 12M | $805.96 | 3.0 | 265.02 | TTM | high |
| PEG | 12M | $1460.54 | 26.7 | 54.72 | TTM | high |
| residual income | 12M | $460.27 | — | — | TTM | high |
| Own P/E history | 12M | $927.39 | 16.9 | 54.72 | TTM | high |
| triangulated | 12M | $1354.80 | 23.6 | 57.31 | Triangulated | high |
| Peer P/B | 3Y | $1075.13 | 2.6 | 416.53 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $2505.70 | 23.6 | 106.00 | Analyst | medium |
| Peer P/S | 3Y | $558.46 | 3.0 | 183.64 | Analyst | medium |
| PEG | 3Y | $2829.30 | 26.7 | 106.00 | Analyst | medium |
| Own P/E history | 3Y | $1796.50 | 16.9 | 106.00 | Analyst | medium |
| Peer P/B | 5Y | $1107.06 | 2.6 | 428.90 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $1962.08 | 23.6 | 83.00 | Analyst | high |
| Peer P/S | 5Y | $437.30 | 3.0 | 143.80 | Analyst | high |
| PEG | 5Y | $2215.47 | 26.7 | 83.00 | Analyst | high |
| Own P/E history | 5Y | $1406.75 | 16.9 | 83.00 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.